The effects of Berberis vulgaris L. and Berberis aristata L. in metabolic syndrome patients: a systematic and meta-analysis study

Arch Physiol Biochem. 2023 Apr;129(2):393-404. doi: 10.1080/13813455.2020.1828482. Epub 2020 Oct 10.

Abstract

Introduction: This meta-analysis study assessed the effects of Berberis vulgaris L. and Berberis aristata L. in patients with metabolic syndrome.

Methods: Data were analysed through "random-effects meta-regression" performance.

Results: The findings indicated that LDL was 0.68 and 2.92 lower in the B. vulgaris L. and B. aristata L.-treated groups versus the controls. The HDL was 0.71-fold higher in the B. aristata L.-treated group versus the controls. The total-cholesterol levels were 1.02 and 2.25 folds lower in the B. vulgaris L. and B. aristata L.-treated groups versus the matched control groups. The triglyceride levels were 1.35 and 1.16-fold lower in the B. vulgaris L. and B. aristata L.-treated groups versus the controls. Glucose was 0.96 and 0.54 folds lower in the B. vulgaris L. and B. aristata L.-treated groups versus the control groups, respectively.

Conclusion: B. vulgaris L. and B. aristata L. have beneficial effects in patients with metabolic syndrome.

Keywords: Berberis aristata L.; Berberis vulgaris L.; metabolic syndrome.

Publication types

  • Meta-Analysis

MeSH terms

  • Berberis*
  • Humans
  • Metabolic Syndrome* / drug therapy
  • Plant Extracts / pharmacology

Substances

  • Plant Extracts